liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
Landtblom, Anne-Marie
Publications (10 of 157) Show all publications
Berntsson, S.-G., Reis, J., Zjukovskaja, C., Tulek, Z., Kristoffersson, A. & Landtblom, A.-M. (2025). Climate change impacts the symptomology and healthcare of multiple sclerosis patients through fatigue and heat sensitivity-A systematic review. Journal of the Neurological Sciences, 474, Article ID 123526.
Open this publication in new window or tab >>Climate change impacts the symptomology and healthcare of multiple sclerosis patients through fatigue and heat sensitivity-A systematic review
Show others...
2025 (English)In: Journal of the Neurological Sciences, ISSN 0022-510X, E-ISSN 1878-5883, Vol. 474, article id 123526Article, review/survey (Refereed) Published
Abstract [en]

Background: Climate change, in terms of global warming and heat waves, might negatively impact people with neurological diseases. Patients with Multiple Sclerosis (MS), which is characterized by heat sensitivity, may therefore have an increased vulnerability. Subsequently, we aimed to specifically investigate the state of knowledge on climate change and MS. Methods: We conducted a literature search in the Pub Med database during 2022-2024 using the search terms "multiple sclerosis" AND "climate ", "climate change", "global warming", "heat waves", and "seasonal variations". A total of 773 scientifical papers were retrieved and scrutinized according to the inclusion/exclusion criteria. Finally, 24 publications were manually selected based on their relevance to the intended topic, covering climate change related heat sensitivity in MS patients, associated healthcare burden, and treatment strategies. Results: Only few publications focused on climate change and its effect on MS. The search yielded 24 articles on effects of climate/environmental heat and seasonal variations on MS. There was both evidence of worsened clinical symptoms as well as negative studies. However, the majority of selected papers, 16/24 (67 %) revealed an impact on MS symptoms/hospitalization from environmental heat. Conclusions: So far there has been limited interest in the vulnerability of MS patients to climate change. The future perspective of increased temperature and heat waves should be highlighted so that authorities prepare health systems to apply to this new, but logical and intuitive, scientific knowledge. As heat sensitivity also seems to affect neurological disorders beyond MS, further research is needed to develop general care strategies in the future.

Place, publisher, year, edition, pages
ELSEVIER, 2025
Keywords
Multiple sclerosis; Climate change; Fatigue; Heat sensitivity; Review
National Category
Neurology
Identifiers
urn:nbn:se:liu:diva-213853 (URN)10.1016/j.jns.2025.123526 (DOI)001491691700001 ()40359743 (PubMedID)2-s2.0-105004700738 (Scopus ID)
Available from: 2025-05-26 Created: 2025-05-26 Last updated: 2025-05-26
Xue, P., Merikanto, I., Delale, E. A., Bjelajac, A., Yordanova, J., Chan, R. N. Y., . . . Benedict, C. (2024). Associations between obesity, a composite risk score for probable long COVID, and sleep problems in SARS-CoV-2 vaccinated individuals. International Journal of Obesity, 48(9), 1300-1306
Open this publication in new window or tab >>Associations between obesity, a composite risk score for probable long COVID, and sleep problems in SARS-CoV-2 vaccinated individuals
Show others...
2024 (English)In: International Journal of Obesity, ISSN 0307-0565, E-ISSN 1476-5497, Vol. 48, no 9, p. 1300-1306Article in journal (Refereed) Published
Abstract [en]

Background: Preliminary data suggests that obesity might hasten the decline in mRNA vaccine-induced immunity against SARS-CoV-2. However, whether this renders individuals with obesity more susceptible to long COVID symptoms post-vaccination remains uncertain. Given sleep's critical role in immunity, exploring the associations between obesity, probable long COVID symptoms, and sleep disturbances is essential. Methods: We analyzed data from a survey of 5919 adults aged 18 to 89, all of whom received two SARS-CoV-2 mRNA vaccinations. Participants were categorized into normal weight, overweight, and obesity groups based on ethnicity-specific BMI cutoffs. The probability of long COVID was evaluated using the Post-Acute Sequelae of SARS-CoV-2 (PASC) score, as our survey did not permit confirmation of acute SARS-CoV-2 infection through methods such as antibody testing. Additionally, sleep patterns were assessed through questionnaires. Results: Participants with obesity exhibited a significantly higher adjusted odds ratio (OR) of having a PASC score of 12 or higher, indicative of probable long COVID in our study, compared to those with normal weight (OR: 1.55, 95% CI: 1.05, 2.28). No significant difference was observed for overweight individuals (OR: 0.92 [95% CI: 0.63, 1.33]). Both obesity and probable long COVID were associated with increased odds of experiencing a heightened sleep burden, such as the presence of obstructive sleep apnea or insomnia (P < 0.001). However, no significant interaction between BMI and probable long COVID status was found. Conclusions: Even post-vaccination, individuals with obesity may encounter a heightened risk of experiencing prolonged COVID-19 symptoms. However, confirming our observations necessitates comprehensive studies incorporating rigorous COVID infection testing, such as antibody assays - unavailable in our anonymous survey. Additionally, it is noteworthy that the correlation between probable long COVID and sleep disturbances appears to be independent of BMI.

Place, publisher, year, edition, pages
SPRINGERNATURE, 2024
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:liu:diva-205426 (URN)10.1038/s41366-024-01556-w (DOI)001243340900001 ()38849462 (PubMedID)
Note

Funding Agencies|Novo Nordisk Foundation [NNF23OC0081873]; Swedish Brain Research Foundation [FO2023-0292]; Ake Wiberg Foundation [M23-0040]; Tore Nilsson Foundation [2023-079]; Signe and Arne Gyllenberg Foundation [5815, 5961]; Uppsala University

Available from: 2024-06-26 Created: 2024-06-26 Last updated: 2025-04-09Bibliographically approved
Lafta, M. S., Sokolov, A. V., Landtblom, A.-M., Ericson, H., Schioeth, H. B. & Abu Hamdeh, S. (2024). Exploring biomarkers in trigeminal neuralgia patients operated with microvascular decompression: A comparison with multiple sclerosis patients and non-neurological controls. European Journal of Pain, 28(6), 929-942
Open this publication in new window or tab >>Exploring biomarkers in trigeminal neuralgia patients operated with microvascular decompression: A comparison with multiple sclerosis patients and non-neurological controls
Show others...
2024 (English)In: European Journal of Pain, ISSN 1090-3801, E-ISSN 1532-2149, Vol. 28, no 6, p. 929-942Article in journal (Refereed) Published
Abstract [en]

BackgroundTrigeminal neuralgia (TN) is a severe facial pain condition often associated with a neurovascular conflict. However, neuroinflammation has also been implicated in TN, as it frequently co-occurs with multiple sclerosis (MS).MethodsWe analysed protein expression levels of TN patients compared to MS patients and controls. Proximity Extension Assay technology was used to analyse the levels of 92 proteins with the Multiplex Neuro-Exploratory panel provided by SciLifeLab, Uppsala, Sweden. Serum and CSF samples were collected from TN patients before (n = 33 and n = 27, respectively) and after (n = 28 and n = 8, respectively) microvascular decompression surgery. Additionally, we included samples from MS patients (n = 20) and controls (n = 20) for comparison.ResultsIn both serum and CSF, several proteins were found increased in TN patients compared to either MS patients, controls, or both, including EIF4B, PTPN1, EREG, TBCB, PMVK, FKBP5, CD63, CRADD, BST2, CD302, CRIP2, CCL27, PPP3R1, WWP2, KLB, PLA2G10, TDGF1, SMOC1, RBKS, LTBP3, CLSTN1, NXPH1, SFRP1, HMOX2, and GGT5. The overall expression of the 92 proteins in postoperative TN samples seems to shift towards the levels of MS patients and controls in both serum and CSF, as compared to preoperative samples. Interestingly, there was no difference in protein levels between MS patients and controls.ConclusionsWe conclude that TN patients showed increased serum and CSF levels of specific proteins and that successful surgery normalizes these protein levels, highlighting its potential as an effective treatment. However, the similarity between MS and controls challenges the idea of shared pathophysiology with TN, suggesting distinct underlying mechanisms in these conditions.SignificanceThis study advances our understanding of trigeminal neuralgia (TN) and its association with multiple sclerosis (MS). By analysing 92 protein biomarkers, we identified distinctive molecular profiles in TN patients, shedding light on potential pathophysiological mechanisms. The observation that successful surgery normalizes many protein levels suggests a promising avenue for TN treatment. Furthermore, the contrasting protein patterns between TN and MS challenge prevailing assumptions of similarity between the two conditions and point to distinct pathophysiological mechanisms.

Place, publisher, year, edition, pages
WILEY, 2024
National Category
Neurology
Identifiers
urn:nbn:se:liu:diva-200252 (URN)10.1002/ejp.2231 (DOI)001133731000001 ()38158702 (PubMedID)
Note

Funding Agencies|Region Uppsala (ALF)

Available from: 2024-01-19 Created: 2024-01-19 Last updated: 2024-11-22Bibliographically approved
Berezin, L., Waseem, R., Merikanto, I., Benedict, C., Holzinger, B., De Gennaro, L., . . . Chung, F. (2024). Habitual short sleepers with pre-existing medical conditions are at higher risk of Long COVID. Journal of Clinical Sleep Medicine (JCSM), 20(1), 111-119
Open this publication in new window or tab >>Habitual short sleepers with pre-existing medical conditions are at higher risk of Long COVID
Show others...
2024 (English)In: Journal of Clinical Sleep Medicine (JCSM), ISSN 1550-9389, E-ISSN 1550-9397, Vol. 20, no 1, p. 111-119Article in journal (Refereed) Published
Abstract [en]

Study Objectives: Preliminary evidence suggests that the risk of Long COVID is higher among people with pre-existing medical conditions. Based on its proven adjuvant role in immunity, habitual sleep duration may alter the risk of developing Long COVID. The objective of this study was to determine whether the odds of Long COVID are higher among those with pre-existing medical conditions, and whether the strength of this association varies by habitual sleep duration. Methods: Using data from 13,461 respondents from 16 countries who participated in the 2021 survey -based International COVID Sleep Study II (ICOSS II), we studied the associations between habitual sleep duration, pre-existing medical conditions, and Long COVID. Results: Of 2,508 individuals who had COVID-19, 61% reported at least 1 Long COVID symptom. Multivariable logistic regression analysis showed that the risk of having Long COVID was 1.8 -fold higher for average -length sleepers (6-9 h/night) with pre-existing medical conditions compared with those without pre-existing medical conditions (adjusted odds ratio [aOR] 1.84 [1.18-2.90]; P = .008). The risk of Long COVID was 3 -fold higher for short sleepers with pre-existing medical conditions (aOR 2.95 [1.04-8.4]; P = .043) and not significantly higher for long sleepers with pre-existing conditions (aOR 2.11 [0.93-4.77]; P = .073) compared with average -length sleepers without pre-existing conditions. Conclusions: Habitual short nighttime sleep duration exacerbated the risk of Long COVID in individuals with pre-existing conditions. Restoring nighttime sleep to average duration represents a potentially modifiable behavioral factor to lower the odds of Long COVID for at -risk patients.

Place, publisher, year, edition, pages
AMER ACAD SLEEP MEDICINE, 2024
Keywords
long COVID; COVID-19; sleep duration; pre-existing medical conditions; International COVID Sleep Study Survey; ICOSS II
National Category
Gynaecology, Obstetrics and Reproductive Medicine
Identifiers
urn:nbn:se:liu:diva-203137 (URN)10.5664/jcsm.10818 (DOI)001199768400019 ()37858285 (PubMedID)
Available from: 2024-04-30 Created: 2024-04-30 Last updated: 2025-02-11
Bjorvatn, B., Merikanto, I., Reis, C., Korman, M., Bjelajac, A. K., Holzinger, B., . . . Forthun, I. (2023). Shift workers are at increased risk of severe COVID-19 compared with day workers: Results from the international COVID sleep study (ICOSS) of 7141 workers. Chronobiology International, 40(2), 114-122
Open this publication in new window or tab >>Shift workers are at increased risk of severe COVID-19 compared with day workers: Results from the international COVID sleep study (ICOSS) of 7141 workers
Show others...
2023 (English)In: Chronobiology International, ISSN 0742-0528, E-ISSN 1525-6073, Vol. 40, no 2, p. 114-122Article in journal (Refereed) Published
Abstract [en]

The present study had two main aims. First, to investigate whether shift/night workers had a higher prevalence and severity of COVID-19 compared with day workers. Second, to investigate whether people regularly working in face-to-face settings during the pandemic exhibited a higher prevalence and severity of COVID-19 compared with those having no need to be in close contact with others at work. Data consisted of 7141 workers from 15 countries and four continents who participated in the International COVID Sleep Study-II (ICOSS-II) between May and December 2021. The associations between work status and a positive COVID-19 test and several indications of disease severity were tested with chi-square tests and logistic regressions adjusted for relevant confounders. In addition, statistical analyses were conducted for the associations between face-to-face work and COVID-19 status. Results showed that shift/night work was not associated with an increased risk of COVID-19 compared to day work. Still, shift/night workers reported higher odds for moderate to life-threatening COVID-19 (adjusted odds ratio (aOR) = 2.71, 95%-confidence interval = 1.23-5.95) and need for hospital care (aOR = 5.66, 1.89-16.95). Face-to-face work was associated with an increased risk of COVID-19 (aOR = 1.55, 1.12-2.14) but not with higher disease severity. In conclusion, shift/night work was not associated with an increased risk of COVID-19, but when infected, shift/night workers reported more severe disease. Impaired sleep and circadian disruption commonly seen among shift/night workers may be mediating factors. Working face-to-face increased the risk of COVID-19, likely due to increased exposure to the virus. However, face-to-face work was not associated with increased disease severity.

Place, publisher, year, edition, pages
TAYLOR & FRANCIS INC, 2023
Keywords
Coronavirus; SARS-CoV-2; night work; shift work; face-to-face work
National Category
Occupational Health and Environmental Health
Identifiers
urn:nbn:se:liu:diva-190814 (URN)10.1080/07420528.2022.2148182 (DOI)000890154000001 ()36412198 (PubMedID)
Available from: 2023-01-04 Created: 2023-01-04 Last updated: 2024-05-03Bibliographically approved
Gauffin, H., Fast, T., Komkova, A., Berntsson, S., Boström, I. & Landtblom, A.-M. (2022). Narcolepsy treatment in Sweden: An observational study. Acta Neurologica Scandinavica, 145(2), 185-192
Open this publication in new window or tab >>Narcolepsy treatment in Sweden: An observational study
Show others...
2022 (English)In: Acta Neurologica Scandinavica, ISSN 0001-6314, E-ISSN 1600-0404, Vol. 145, no 2, p. 185-192Article in journal (Refereed) Published
Abstract [en]

Objectives To describe the pharmacological treatments (2005-2017) and the healthcare utilization (1997-2016) for patients with narcolepsy in Sweden in order to create a framework for future organizational and economic analyses. Material & Methods Patients of all ages with a diagnosis of narcolepsy registered in the National Patient Registry in specialist care in Sweden were included and information on treatments for narcolepsy was retrieved from The Swedish Prescribed Drug Register. Results We collected 2508 patients with narcolepsy, 43,3% men and 56,7% women and 47,9% were prescribed modafenil, 33,8% metylphenidate and 26,2% amphetamine. In total, 3817 treatments were initiated. Patients treated with amphetamine had a higher mean age. More women than men used modafinil, methylphenidate, amphetamine and antidepressants. The narcolepsy population had more outpatient than inpatient healthcare. Patients treated with sodium oxybate had more outpatient visits than other narcolepsy patients, before and during treatment (p = .00). Conclusions This study gives valuable information on pharmaceutical treatments and healthcare utilization for patients with narcolepsy and can be used to estimate the healthcare cost in the future. Patients with sodium oxybate treatment had more outpatient visits than other patients before and during treatment which may be due to the need to monitor potentially severe side-effects or may indicate that patients with sodium oxybate treatment have a severe disease. The number of included patients was less than expected; however, this may depend on patients escaping our collection of data, which does not contain information from primary care.

Place, publisher, year, edition, pages
Wiley, 2022
Keywords
narcolepsy; neuropharmacology; sleep disorders; treatment
National Category
Nursing
Identifiers
urn:nbn:se:liu:diva-180361 (URN)10.1111/ane.13532 (DOI)000703860800001 ()34611886 (PubMedID)
Note

Funding Agencies|UCBUCB Pharma SA

Available from: 2021-10-18 Created: 2021-10-18 Last updated: 2023-05-04
Roodakker, K. R., Ezra, B., Gauffin, H., Latini, F., Zetterling, M., Berntsson, S. & Landtblom, A.-M. (2021). Erratum to "Ecstatic and gelastic seizures related to the hypothalamus"  [Epilepsy Behav. Rep. 14 (2020) 100358]. Epilepsy & Behavior Reports, 15, Article ID 100399.
Open this publication in new window or tab >>Erratum to "Ecstatic and gelastic seizures related to the hypothalamus"  [Epilepsy Behav. Rep. 14 (2020) 100358]
Show others...
2021 (English)In: Epilepsy & Behavior Reports, E-ISSN 2589-9864, Vol. 15, article id 100399Article in journal (Other academic) Published
Abstract [en]

n/a

Place, publisher, year, edition, pages
Elsevier Science INC, 2021
Identifiers
urn:nbn:se:liu:diva-176131 (URN)10.1016/j.ebr.2020.100399 (DOI)000653024400031 ()33437957 (PubMedID)
Available from: 2021-06-07 Created: 2021-06-07 Last updated: 2023-03-17
Landtblom, A.-M., Berntsson, S. G., Boström, I. & Iacobaeus, E. (2021). Multiple sclerosis and COVID-19: The Swedish experience. Acta Neurologica Scandinavica, 144(3), 229-235
Open this publication in new window or tab >>Multiple sclerosis and COVID-19: The Swedish experience
2021 (English)In: Acta Neurologica Scandinavica, ISSN 0001-6314, E-ISSN 1600-0404, Vol. 144, no 3, p. 229-235Article, review/survey (Refereed) Published
Abstract [en]

The COVID-19 pandemic has brought challenges for healthcare management of patients with multiple sclerosis (MS). Concerns regarding vulnerability to infections and disease-modifying therapies (DMTs) and their complications have been raised. Recent published guidelines on the use of DMTs in relation to COVID-19 in MS patients have been diverse between countries with lack of evidence-based facts. In Sweden, there exists a particular interest in anti-CD20 therapy as a possible risk factor for severe COVID-19 due to the large number of rituximab-treated patients off-label in the country. Rapid responses from the Swedish MS Association (SMSS) and the Swedish MS registry (SMSreg) have resulted in national guidelines on DMT use for MS patients and implementation of a COVID-19 module in the SMSreg. Recently updated guidelines also included recommendations on COVID-19 vaccination with regard to the different DMTs. Social distancing policies forced implementation of telemedicine consultation to replace in-person consultations as part of regular MS health care. Patient-reported outcome measures (PROMs) in SMSreg have been useful in this respect. This paper reports our experiences on the progress of national MS health care during the COVID-19 pandemic, in addition to offering an overview of the present scientific context.

Place, publisher, year, edition, pages
WILEY, 2021
Keywords
COVID-19; disease-modifying therapies; healthcare management; multiple sclerosis; risk groups
National Category
Nursing
Identifiers
urn:nbn:se:liu:diva-176468 (URN)10.1111/ane.13453 (DOI)000653217100001 ()34028810 (PubMedID)
Available from: 2021-06-15 Created: 2021-06-15 Last updated: 2022-05-25
Berntsson, S. G., Kristoffersson, A., Daniilidou, M., Dahl, N., Ekstrom, C., Semnic, R., . . . Landtblom, A.-M. (2020). Aniridia with PAX6 mutations and narcolepsy. Journal of Sleep Research, 29(6), Article ID e12982.
Open this publication in new window or tab >>Aniridia with PAX6 mutations and narcolepsy
Show others...
2020 (English)In: Journal of Sleep Research, ISSN 0962-1105, E-ISSN 1365-2869, Vol. 29, no 6, article id e12982Article in journal (Refereed) Published
Abstract [en]

PAX6 gene mutations cause a variety of eye and central nervous system (CNS) abnormalities. Aniridia is often accompanied by CNS abnormalities such as pineal gland atrophy or hypoplasia, leading to disturbed circadian rhythm and sleep disorders. Less is known on the coincidence of narcolepsy in this patient group. We aimed to find out whether the circadian rhythm or sleep-wake structure was affected in patients with aniridia. Four members of a family segregating with congenital aniridia in two generations were included in the study. The patients were subjected to genetic testing for a PAX6 mutation, multiple sleep latency test, whole-brain magnetic resonance imaging (MRI), hypocretin-1 in cerebrospinal fluid, and Human Leukocyte Antigen DQ beta1*06:02. All four members were heterozygous for the pathogenic c.959-1Gamp;gt;A mutation in the PAX6 gene. Sleep disturbance was observed in all family members. The index patient was diagnosed with narcolepsy. MRI showed a hypoplastic pineal gland in all members. We describe the first case of a patient with PAX6 haploinsufficiency, aniridia and pineal gland hypoplasia diagnosed with narcolepsy type-1, suggesting a complex sleep disorder pathogenesis.

Place, publisher, year, edition, pages
WILEY, 2020
Keywords
absence of iris; narcolepsy; PAX6 haploinsufficiency; pineal gland atrophy
National Category
Neurology
Identifiers
urn:nbn:se:liu:diva-163415 (URN)10.1111/jsr.12982 (DOI)000507560500001 ()31943460 (PubMedID)
Note

Funding Agencies|Swedish Research Council SRCSwedish Research Council [2015-4870, 201502424]; Hjarnfonden [FO2019-0210]

Available from: 2020-02-04 Created: 2020-02-04 Last updated: 2021-04-29
Bolin, K., Niska, P.-A., Pirhonen, L., Wasling, P. & Landtblom, A.-M. (2020). The cost utility of pitolisant as narcolepsy treatment. Acta Neurologica Scandinavica, 141(4), 301-310
Open this publication in new window or tab >>The cost utility of pitolisant as narcolepsy treatment
Show others...
2020 (English)In: Acta Neurologica Scandinavica, ISSN 0001-6314, E-ISSN 1600-0404, Vol. 141, no 4, p. 301-310Article in journal (Refereed) Published
Abstract [en]

Objectives The cost-effectiveness of available pharmacological treatments for narcolepsy is largely unknown. Available pharmacological treatments are associated with tolerability, abuse, and adherence issues. Pitolisant is the first inverse agonist of the histamine H3 receptor to be prescribed for the treatment of narcolepsy with and without cataplexy. Studies suggest that pitolisant is both as effective as previously introduced drugs and is associated with fewer adverse effects. The objective in this study was to estimate the cost-effectiveness of pitolisant as monotherapy, and pitolisant as an adjunctive treatment to modafinil, compared with standard treatment. Materials amp; Methods Calculations were performed using a Markov model with a 50-year time horizon. Healthcare utilization and quality-adjusted life years (QALYs) for each treatment alternative were calculated assuming no treatment effect on survival. Probabilistic sensitivity analyses were performed for treatment effectiveness and healthcare cost parameters. Results The cost per additional quality-adjusted life year was estimated at SEK 356 337 (10 SEK approximate to 1 Euro) for pitolisant monotherapy, and at SEK 491 128 for pitolisant as an adjunctive treatment, as compared to standard treatment. The cost-effectiveness measure was demonstrated to be particularly sensitive to the assumptions made concerning indirect effects on total healthcare utilization and the pitolisant treatment cost. Conclusions The incremental cost-effectiveness ratios were below the unofficial willingness-to-pay threshold at SEK 500 000. The estimated costs per additional QALY obtained here are likely to overestimate the true cost-effectiveness ratio since significant potential indirect effects-pertaining both to labor-market and household-related productivity-of treatment are not taken into account.

Place, publisher, year, edition, pages
WILEY, 2020
Keywords
cost-effectiveness; narcolepsy; pitolisant
National Category
Surgery
Identifiers
urn:nbn:se:liu:diva-163413 (URN)10.1111/ane.13202 (DOI)000507515100001 ()31838740 (PubMedID)
Note

Funding Agencies|AOP Orphan Pharmaceuticals AG

Available from: 2020-02-04 Created: 2020-02-04 Last updated: 2021-04-29
Organisations

Search in DiVA

Show all publications